AstraZeneca Tozorakimab Tops Late-Stage COPD Trials
AstraZeneca tozorakimab met primary endpoints in late-stage OBERON and TITANIA, spurring investor optimism ahead of full data presentation.
KEY TAKEAWAYS
- Tozorakimab met primary endpoints in OBERON and TITANIA, cutting annualized moderate-to-severe COPD exacerbations.
- Efficacy was consistent across blood eosinophil counts and lung-function severity stages.
- AstraZeneca reported a favorable safety profile and plans full data presentation; PROSPERO and MIRANDA toplines expected H1 2026.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
AstraZeneca plc said on March 27, 2026 (ET) that tozorakimab significantly reduced annualized moderate-to-severe chronic obstructive pulmonary disease (COPD) exacerbations in Phase 3 OBERON and TITANIA trials. The company reported a favorable safety profile and plans to present full data at a medical meeting.
Phase 3 Topline Results and Safety Profile
The two pivotal studies met their primary endpoint in the pre-specified population of former smokers and showed benefit across the overall enrolled population of former and current smokers. Efficacy was consistent across all blood eosinophil levels and lung-function severity stages. Tozorakimab was administered as a 300 mg subcutaneous dose alongside patients’ standard inhaled maintenance therapy in the OBERON (NCT05166889) and TITANIA (NCT05158387) trials.
Tozorakimab is a first-in-class monoclonal antibody targeting interleukin-33 (IL-33) in both its reduced and oxidized forms, a cytokine implicated in airway inflammation and mucus production in COPD. AstraZeneca described the drug as generally well tolerated with a favorable safety and tolerability profile.
Pipeline Developments and Competitive Positioning
AstraZeneca is evaluating tozorakimab beyond COPD, including studies in severe viral lower respiratory tract disease and asthma. The company positions the drug as mechanistically differentiated through broader inhibition of the ST2, RAGE, and EGFR pathways compared with competitors.
Other IL-33 or related therapies have shown mixed results. Sanofi and Regeneron’s itepekimab posted one positive and one negative trial outcome, while Roche’s astegolimab showed a positive Phase 2b result but a negative Phase 3 outcome. AstraZeneca has not disclosed regulatory submissions related to these Phase 3 results.
Two additional Phase 3 studies are ongoing: PROSPERO, an open-label extension of OBERON and TITANIA, and MIRANDA, a frequent-dosing study in exacerbation-prone COPD patients. Topline results from both are expected in the first half of 2026.
Analyst estimates external to company guidance have projected peak sales for tozorakimab in the $3 billion to $5 billion range.
